Results 141 to 150 of about 27,407 (265)

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard, Marietta Kokla, Rebekka H. Gerwig, Hatice Isik Mizrak, Sofie Korsgaard Hecquet, Tik Muk, Gurjeet Kaur, Birgitte Brock, Christian Stevns Hansen, Joachim Størling   +9 more
wiley   +1 more source

From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor. [PDF]

BMC Nephrol
Castellanos-de la Hoz J, Molano-Triviño A, González-García YF, Espinosa Saltaren LM, Zúñiga-Rodríguez E.   +4 more
europepmc   +1 more source

Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross‐Sectional Analysis From the VOLTAIRE Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To characterise baseline clinical, anatomical, and genetic cardiovascular risk profiles in participants enrolled in the VOLTAIRE (Evaluation of Polygenic Scores and CT Imaging in Risk Factor Modification in Patients with Type 2 Diabetes) study and examine concordance across these domains. Methods This analysis included adults with T2D who
Ruofei (Trophy) Chen, Adam J. Nelson, Sophia Zoungas, Robyn A. Clark, Sean Tan, Esther F. Davis, Melissa C. Southey, Andrew Lin, Giuseppe Di Giovanni, Masashi Fujino, Jennifer Wong, Robert L. O'Reilly, Jacqueline S. Dron, Stephen J. Nicholls   +13 more
wiley   +1 more source

The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management. [PDF]

Front Endocrinol (Lausanne)
Deng B, Liu W, Chu Q.
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Barriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England. [PDF]

Clin Kidney J
Dattani R, Purssell N, Desilva R, Joshi M, Frankel AH, Ashrafian H, Darzi A, Tam FWK.   +7 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Current practices of SGLT2 inhibitor use and ketone monitoring in intensive care units: A multicentre observational study. [PDF]

Crit Care Resusc
Sasaki T, Micallef S, Wang AY, Butt F, Hammond NE, Hardie M, Knowles S, Yokoo T, Gallagher M, George Institute for Global Health and the Australian and New Zealand Intensive Care Society Clinical Trials Group.   +9 more
europepmc   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source